Clinical Investigators Focusing on benefits of Reolysin, Kyprolis Combination in Multiple Myeloma

Clinical Investigators Focusing on benefits of Reolysin, Kyprolis Combination in Multiple Myeloma

Oncolytics Biotech’s virus-based anti-cancer therapy Reolysin (pelareorep) has the attention of top researchers from Winship Cancer Center and City of Hope who are studying how combinations including pelareorep and Kyprolis (carfilzomib) offer benefits to multiple myeloma patients.

The Roth Capital Partners Sponsored Call

Investment bank Roth Capital Partners sponsored a call for the discussion featuring two key principal investigators including Craig Hofmeister, MD associate professor at the Winship Cancer Institute at Emory University School of Medicine, and Flavia Pichiorri, MD, associate professor, City of Hope and reported by Myeloma Research News.

The Background Evidence

These investigators are referring to preclinical studies (e.g., lab and animals) and a Phase I clinical trial studying the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does not respond to treatment (refractory). The study sponsor, National Cancer Institute (part of NIH), noted that drugs used in chemotherapy, such as dexamethasone and carfilzomib, wo...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee